RIPK1 and metabolic dysfunction-associated steatohepatitis: With ongoing advances of increasing number of RIPK1 inhibitors in human clinical studies for the treatment of many human inflammatory and degenerative diseases16, we expect that preventing hepatocyte apoptosis by RIPK1 inhibitors may represent a promising approach to treat NASH-associated liver damage and fibrosis.